Corient Private Wealth
IHE icon

Corient Private Wealth’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Corient Private Wealth’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$650K Buy
6,561
+72
+1% +$6.49K ﹤0.01% 2059
2026
Q1 		$562K Sell
6,489
-17
-0.3% -$1.49K ﹤0.01% 1965
2025
Q4 		$552K Buy
6,506
+198
+3% +$15.8K ﹤0.01% 1819
2025
Q3 		$458K Buy
+6,308
New +$435K ﹤0.01% 1845

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Corient Private Wealth's IHE Position: Q2 2026 in Review

Corient Private Wealth increased its iShares US Pharmaceuticals ETF (IHE) stake by 1.1% in Q2 2026, buying an estimated $6.49K and bringing the position to 6,561 shares worth $650K. The position accounts for ﹤0.01% of the portfolio, ranked #2059.

Corient Private Wealth first reported a position in IHE in Q3 2025 and has held it in 4 quarters since. 210 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

  • Corient Private Wealth held 6,561 shares of iShares US Pharmaceuticals ETF worth $650K as of Q2 2026.
  • Corient Private Wealth bought 72 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $6.49K.
  • iShares US Pharmaceuticals ETF made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2059 holding.
  • Corient Private Wealth first reported a position in iShares US Pharmaceuticals ETF in Q3 2025 and has held it in 4 quarters since.
  • 210 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.